Stockchase Opinions

Andrew McCreath Eyetech Pharmaceuticals EYET-Q DON'T BUY Jan 17, 2005

He is shorting with a paired/trade situation being long on QLT. Going to have problems in generating the optimistic revenue line that people are expecting.
$39.400

Stock price when the opinion was issued

biotechnology pharmaceutical
It's the ideal tool to help you make quicker, more informed decisions for managing and tracking your investments.